CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of bladder cancer.
  
  LEARNING OBJECTIVES

  • Consider data supporting the use of anti-PD-1 antibody therapy for high-risk non-muscle-invasive bladder cancer (NMIBC) that is unresponsive to BCG, and determine how this strategy can be appropriately integrated into patient care.
  • Evaluate the recent FDA approval of adjuvant anti-PD-1 antibody therapy for patients with high-risk muscle-invasive bladder cancer (MIBC), and understand the current role of this strategy.
  • Recognize how biologic and patient-specific factors influence the selection and sequencing of treatment for metastatic urothelial bladder carcinoma (UBC).
  • Review available clinical trial evidence with immune checkpoint inhibitors as monotherapy or as maintenance after platinum-based chemotherapy for newly diagnosed metastatic UBC, and recognize the utility of these agents in practice.
  • Recall pivotal trial findings leading to the FDA approval of novel compounds with unique mechanisms of action for previously treated locally advanced or metastatic UBC, and discuss with patients why these agents would be appropriate.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for advanced or metastatic UBC.
  • Develop an understanding of the biologic rationale for, research findings with and ongoing studies evaluating promising agents and strategies for NMIBC, MIBC and metastatic UBC.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY & MODERATOR — The following faculty reported relevant financial relationships with ineligible entities:
  
  FACULTY
  
  Matthew D Galsky, MD
  Professor of Medicine
  Icahn School of Medicine at Mount Sinai
  Co-Leader, Bladder Cancer Center of Excellence
  Associate Director, Translational Research
  The Tisch Cancer Institute
  New York, New York
  
  Advisory Committee: Aileron Therapeutics Inc, Alligator Bioscience, Astellas, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, BioMotiv, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals Inc, Dracen Pharmaceuticals, Dragonfly Therapeutics, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Infinity Pharmaceuticals Inc, Inovio Pharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck, Novartis, Numab, Pfizer Inc, Seagen Inc, UroGen Pharma; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck.
  
  Ashish M Kamat, MD, MBBS
  Professor of Urologic Oncology (Surgery)
  Wayne B Duddlesten Professor of Cancer Research
  Department of Urology, Division of Surgery
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  No relevant conflicts of interest to disclose.
  
  Stephen B Williams, MD, MS
  Medical Director, High Value Care
  UTMB Health System
  Chief, Division of Urology
  Professor (Tenured), Urology and Radiology
  Robert Earl Cone Professorship
  Director of Urologic Oncology
  Director of Urologic Research
  Co-Director of the Surgical Outcomes Research Division
  The University of Texas Medical Branch
  Galveston, Texas
  
  No relevant conflicts of interest to disclose.
  
  MODERATOR
  
  Sumanta Kumar Pal, MD
  Professor, Department of Medical Oncology and Therapeutics Research
  City of Hope
  Duarte, California
  
  No relevant conflicts of interest to disclose.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.
  
  Release date: May 2022
  Expiration date: May 2023